Drugs / GRT-C903
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06253520 | May 2024 → Feb 2029 expected | breast cancer, colorectal cancer, malignant urinary system neoplasm, metastatic neoplasm +2 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03953235 | Jul 2019 → Mar 2023 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Gritstone bio, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRT-C903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253520 ↗ |